Beyond Air, Inc. filings document the regulatory record for a commercial-stage nitric oxide medical device and biopharmaceutical company. Proxy materials cover stockholder votes on charter amendments, reverse stock-split authority, director elections, auditor ratification, and equity incentive plan share reserves.
Form 8-K disclosures record material events such as executive officer transitions, separation agreements, Nasdaq continued-listing compliance notices, annual meeting results, material agreements, capital-structure matters, operating and financial results, and clinical or regulatory disclosures tied to the company's nitric oxide programs.
Beyond Air, Inc. Schedule 13G/A: Alyeska Investment Group, L.P., Alyeska Fund GP, LLC and Anand Parekh report 0 shares beneficially owned of Common Stock (CUSIP 08862L202), representing 0.00% of the class. The filing is a joint amendment pursuant to Rule 13d-1(k).
The cover shows an amendment dated 03/31/2026 and signatures dated 05/15/2026. The filers state ownership is five percent or less of the class and list their principal office at 77 West Wacker Drive, Chicago, IL.
Balyasny Asset Management and related entities report beneficial ownership of 763,266 shares of Beyond Air, Inc. Common Stock, representing approximately 7.25% of the class. The total includes 299,104 shares issuable upon exercise of Warrants subject to a Beneficial Ownership Limitation that restricts exercises above 9.99%. The 10,529,344 Shares outstanding as of February 10, 2026 is cited as the basis for the percentage. The ownership is held on behalf of Atlas Diversified Master Fund, Ltd. and disclosed through BAM, BAM GP, BAM Holdings, Dames, and Dmitry Balyasny.
Beyond Air, Inc. is calling a special stockholder meeting on June 18, 2026 to approve a reverse stock split of its common stock at a ratio between 1-for-2 and 1-for-20, at the Board’s discretion, and to approve a related adjournment proposal.
The company received a Nasdaq notice on April 7, 2026 for failing the $1.00 minimum bid price requirement, after its shares traded below $1.00 for 30 consecutive business days. Because it previously completed a 1-for-20 reverse split on July 14, 2025, it is not eligible for the standard compliance period and faces potential delisting unless a Nasdaq Hearings Panel grants continued listing.
The Board views the reverse split as a way to raise the share price to meet Nasdaq rules and support future capital raising. As of the April 20, 2026 record date, there were 12,692,684 shares of common stock outstanding, each entitled to one vote at the meeting.
Beyond Air, Inc. (XAIR) is asking shareholders to approve a Fourth Amendment to its charter that would permit the Board, within one year, to implement a reverse stock split of Common Stock at a ratio between 1-for-2 and 1-for-20 (Proposal 1). The company reported 13,192,684 shares outstanding as of the April 20, 2026 record date and disclosed the last reported sale price was $0.5450, below Nasdaq’s $1.00 minimum bid requirement. The Board states it intends to effect the reverse split if needed to address Nasdaq noncompliance, subject to Board discretion and market conditions. A second proposal seeks authority to adjourn the Special Meeting to solicit additional proxies if votes are insufficient (Proposal 2). The Special Meeting is scheduled for June 18, 2026.
Beyond Air, Inc. has received written notice from Nasdaq that its common stock is not in compliance with the $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2), which is required for continued listing.
The company has requested a hearing before the Nasdaq Hearings Panel, which has been scheduled for May 14, 2026. This timely request stays any suspension or delisting action until the Panel issues a written decision, so the stock is expected to remain listed on Nasdaq during the hearing process.
The company cautions that there is no assurance the Panel will grant continued listing or that it will regain compliance with Nasdaq’s continued listing standards, and it includes forward-looking statement disclaimers referencing risks described in its Form 10-K and other SEC filings.
Beyond Air, Inc. reported that it received a Nasdaq notice on April 7, 2026 stating its common stock no longer meets the minimum $1.00 per-share bid price required by Nasdaq Listing Rule 5550(a)(2). The deficiency was triggered because the stock’s closing bid price stayed below $1.00 for thirty consecutive business days from February 23, 2026 to April 6, 2026, which violates the Bid Price Rule.
Because the company previously effected a 1-for-20 reverse stock split on July 14, 2025, Nasdaq rules make it ineligible for the usual 180-day cure period. As a result, its securities are subject to delisting unless it requests a hearing with the Nasdaq Hearings Panel by April 14, 2026. Beyond Air plans to request this hearing, which would automatically stay any suspension or delisting while the Panel reviews the case. During this appeal process, the stock is expected to continue trading on Nasdaq.
The company says it will closely track its bid price and is considering options to regain compliance with Nasdaq’s listing standards, including potentially using another reverse stock split. However, it cautions there is no assurance the Panel will grant continued listing or that compliance can be regained and maintained, underscoring a meaningful risk around its Nasdaq listing status.
Beyond Air, Inc. announced a leadership transition in which longtime CEO and director Steven A. Lisi resigned from all positions, effective March 27, 2026, and Robert Goodman, previously Chief Commercial Officer and a director, was appointed CEO. The company states Mr. Lisi’s resignation is not due to any disagreement with its operations or policies.
Under a Separation and Release of Claims Agreement, after a seven-business-day revocation period, Beyond Air will provide Mr. Lisi $650,000 in separation pay over 12 months and pay his COBRA premiums for 12 months. All of his unvested stock options and restricted stock unit awards as of March 27, 2026, will fully vest and remain exercisable for 24 months. The company has not yet entered into a new employment agreement with Mr. Goodman and reports no material changes to his existing compensation at this time.
Alyeska Investment Group and affiliates report a 7.27% stake in Beyond Air, Inc. common stock as of December 31, 2025. They beneficially own 582,638 shares, with no sole voting or dispositive power and full authority shared among the reporting persons.
The holding consists of 224,193 shares of common stock and 358,445 PIPE shares, based on 8,009,488 shares of common stock outstanding cited from a December 16, 2025 prospectus. The group states the position is held in the ordinary course of business and not for influencing control.
Balyasny-affiliated investment entities have disclosed a significant passive stake in Beyond Air, Inc. They report beneficial ownership of 763,266 shares of common stock, including 299,104 shares issuable upon exercise of warrants, representing approximately 9.53% of Beyond Air’s outstanding common shares.
The shares are held by Atlas Diversified Master Fund, Ltd., for which Balyasny Asset Management L.P. acts as investment manager. Related entities GP LLC, Balyasny Asset Management Holdings LP, Dames GP LLC, and individual Dmitry Balyasny may be deemed to share voting and investment power. The warrants are subject to a 9.99% beneficial ownership blocker, limiting exercises that would push ownership above that level. The reporting parties certify that the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Beyond Air.
Beyond Air, Inc. reported fiscal third-quarter 2026 revenue of $2.2 million, up 105% from $1.1 million a year earlier, driven by growing adoption of its LungFit PH nitric oxide system in the U.S. and abroad. Gross profit improved to $0.3 million from a gross loss of $0.2 million.
Operating costs declined, with research and development down to $2.4 million and selling, general and administrative expenses reduced to $4.5 million. Net loss attributable to common stockholders narrowed to $7.3 million, or $0.85 per share, compared with a $13.0 million loss, or $2.96 per share, in the prior-year quarter.
The company ended the quarter with $17.8 million in cash, cash equivalents, restricted cash and marketable securities, plus $4.5 million of net proceeds from a subsequent private placement, and believes this supports a cash runway into calendar 2027. It maintained fiscal 2026 revenue guidance of $8–10 million and reported total long-term debt of $22.0 million.
Beyond Air highlighted commercial milestones, including its first LungFit PH sale to a VA Medical Center and international distribution now covering 40 countries. It also noted a binding agreement under which XTL Biopharmaceuticals will acquire 85% of NeuroNOS, with Beyond Air eligible for $1.0 million in cash, up to $31.5 million in milestones, and 19.9% equity in XTL.